

## PROVINCIAL FUNDING SUMMARY

Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (pCODR 10064)

pERC Recommendation: Recommends with conditions for third line and beyond  
Does not recommend for second line.

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: April 18, 2016

This information is current as of March 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Nov 1, 2017	<p>Adult patients with Philadelphia chromosome-negative (Ph-) pre-B cell acute lymphoblastic leukemia (ALL):</p> <ul style="list-style-type: none"> <li>Relapsed or refractory after at least two prior lines of therapy</li> <li>Refractory to induction and no response to or relapse post salvage chemotherapy</li> <li>Relapse within 12 months of first remission (CR1) and no response to second line or salvage chemotherapy</li> <li>Relapse <math>\geq</math> 6 months post allo-HSCT; no active GVHD and no immunosuppressive medications</li> <li>ECOG PS: 0-2</li> <li>Available social support and ability to safely receive blinatumomab via an out-patient pump</li> <li>No clinically relevant CNS pathology or active CNS disease</li> <li>Alkaline Phosphatase, AST, ALT <math>&lt;</math> 5 X ULN; Total Bilirubin <math>&lt;</math> 1.5 ULN; Serum creatinine <math>&lt;</math> 1.5 ULN.</li> <li>Prescribed by Leukemia/BMT Program physicians and delivered at Vancouver General Hospital</li> </ul> <p>NOTE: A BCCA "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment (please refer to <a href="https://cap.phsa.ca/">https://cap.phsa.ca/</a>).</p>
AB	Under provincial consideration		
SK	Funded	Aug 2, 2017	<p>Treatment of adult patients with Philadelphia chromosome negative relapsed or refractory B precursor acute lymphoblastic leukemia (ALL) who have had at least two prior lines of therapy.</p>

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
MB	Funded	Feb 15, 2017	For the treatment of adult patients with Philadelphia chromosome negative relapsed or refractory B precursor acute lymphoblastic leukemia (ALL) and who have had at least two prior lines of therapy.
ON	Funded	Apr 24, 2017	For treatment of adult patients with Philadelphia chromosome negative relapsed or refractory B precursor acute lymphoblastic leukemia (ALL) and who have had at least two prior lines of therapy
NS	Funded	Feb 1, 2018	As a single agent treatment option in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B precursor acute lymphoblastic leukemia (ALL). Treatment should be for patients with a good performance status and should be treated for two cycles of induction and 3 cycles of consolidation.
NB	Funded	Aug 24, 2017	For the treatment of adult patients with Philadelphia chromosome negative (Ph-) relapsed or refractory B precursor acute lymphoblastic leukemia who have received at least two prior lines of systemic therapy and who have a good performance status. Treatment should be continued until unacceptable toxicity, disease progression or a maximum of 5 cycles.
NL	Under provincial consideration		
PEI	Under provincial consideration		

*Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.